ABBV

AbbVie Inc.

176.09 USD
+0.95 (+0.54%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AbbVie Inc. stock is up 5.13% since 30 days ago. The dividend yield is 3.55% and its next earnings date is Apr 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 11 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 Feb 16:35 16 Aug, 2024 175.00 CALL 30 901
21 Feb 17:07 21 Jun, 2024 165.00 CALL 20 2525
21 Feb 20:36 19 Apr, 2024 170.00 PUT 100 642
21 Feb 20:46 21 Jun, 2024 180.00 CALL 255 3141
21 Feb 20:46 21 Jun, 2024 180.00 CALL 44 3141
22 Feb 15:43 15 Mar, 2024 150.00 CALL 10 3031
22 Feb 16:38 21 Jun, 2024 175.00 CALL 29 2415
22 Feb 16:45 17 Jan, 2025 145.00 CALL 10 10327
22 Feb 16:52 19 Apr, 2024 155.00 CALL 13 380
22 Feb 16:52 21 Jun, 2024 160.00 CALL 13 2541

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

  • Truist Securities
    Tue Feb 6, 09:13
    buy
    confirm
  • Raymond James
    Tue Feb 6, 03:24
    buy
    confirm
  • BMO Capital
    Mon Feb 5, 08:55
    buy
    confirm
  • Raymond James
    Mon Feb 5, 07:22
    buy
    confirm
  • Barclays
    Mon Feb 5, 06:54
    buy
    confirm
  • William Blair
    Mon Jan 29, 09:38
    buy
    upgrade